probenecid has been researched along with Disease Models, Animal in 69 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Development of autosomal dominant polycystic kidney disease (ADPKD) involves renal epithelial cell abnormalities." | 5.91 | Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease. ( Arkhipov, SN; Harris, PC; Ilatovskaya, DV; Pavlov, TS; Potter, DL; Sultanova, RF, 2023) |
| "Probenecid treatment resulted in lower disease scores as compared to EAE animals." | 5.43 | Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis. ( Hainz, N; Meier, C; Tschernig, T; Wolf, S, 2016) |
| " Controls over a 15-weeks period showed that this dosage did prevent the development of syphilitic orchitis and reactivity to the quantitative FTA-ABS-test." | 5.25 | [The effect of pivampicillin and probenecid on experimental syphilis in rabbits]. ( Petzoldt, D, 1975) |
| "Probenecid has been used for decades in the treatment of gout but recently has also been found to improve outcomes in patients with heart failure via stimulation of the transient receptor potential vanilloid 2 (TRPV2) channel in cardiomyocytes." | 3.96 | Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy. ( Koch, SE; Kranias, EG; Liu, G; McDermott, MR; Onusko, E; Robbins, N; Rubinstein, J, 2020) |
| " This has led to the hypothesis that uric acid may contribute to renal fibrosis and progressive renal disease." | 3.76 | Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells. ( Junwei, Y; Lei, J; Li, F; Mingxia, X; Ping, W; Ruoyun, T; Weichun, H; Xiaohua, W; Yang, Z, 2010) |
| "Development of autosomal dominant polycystic kidney disease (ADPKD) involves renal epithelial cell abnormalities." | 1.91 | Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease. ( Arkhipov, SN; Harris, PC; Ilatovskaya, DV; Pavlov, TS; Potter, DL; Sultanova, RF, 2023) |
| "Gastroesophageal reflux disease (GERD) is a common gastrointestinal disorder." | 1.62 | Role of transient receptor potential vanilloid subtype 2 in lower oesophageal sphincter in rat acid reflux oesophagitis. ( Kato, S; Matsui, K; Matsumoto, K; Mizutani, Y; Nakamoto, T; Suenaga, M; Yoshida, A, 2021) |
| "Probenecid was also able to reduce pressure overload-induced mortality and restore indices of disease severity in a rat chronic HF model in vivo." | 1.62 | AIM2-driven inflammasome activation in heart failure. ( Baranyai, T; Brenner, GB; Ferdinandy, P; Giricz, Z; Görbe, A; Gyöngyösi, M; Horváth, IG; Koncsos, G; Kucsera, D; Leszek, P; Makkos, A; Merkely, B; Novák, J; Onódi, Z; Radovits, T; Ruppert, M; Sayour, AA; Schulz, R; Tóth, VE; Varga, ZV, 2021) |
| "Hyperuricemia is a central risk factor for gout and increases the risk for other chronic diseases, including cardiometabolic disease, kidney disease, and hypertension." | 1.56 | High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout. ( Dai, S; Guo, Y; Hong, F; Li, L; Liu, G; Pan, S; Qiao, X; Wang, J; Xie, X; Xu, P; Xue, T; Zhai, Y; Zheng, A, 2020) |
| "Probenecid is a pannexin-1 antagonist and a probenecid therapy was investigated." | 1.46 | Probenecid-treatment reduces demyelination induced by cuprizone feeding. ( Becker, P; Beisswenger, C; Hainz, N; Meier, C; Rapp, D; Tschernig, T; Wagenpfeil, S; Wonnenberg, B, 2017) |
| "Probenecid treatment resulted in lower disease scores as compared to EAE animals." | 1.43 | Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis. ( Hainz, N; Meier, C; Tschernig, T; Wolf, S, 2016) |
| "Paeonol treatment decreased MPTP/p‑induced oxidative stress, as determined by evaluating the activity levels of superoxide dismutase, catalase and glutathione." | 1.43 | Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice. ( Chen, YH; Liu, H; Qu, HD; Shi, X, 2016) |
| "Probenecid has been widely used in the treatment of gout, but evidence suggests that it may also have antinociceptive effects in different inflammatory and pain conditions." | 1.42 | Effect of probenecid on the pain-related behaviour and morphological markers in orofacial formalin test of the rat. ( Bohár, Z; Fejes-Szabó, A; Nagy-Grócz, G; Párdutz, Á; Pődör, B; Tajti, J; Tar, L; Toldi, J; Vámos, E; Vécsei, L, 2015) |
| " Chronic administration of the compound, JZL184 (8 mg/kg), prevented MPTPp-induced motor impairment and preserved the nigrostriatal pathway." | 1.40 | Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. ( Aymerich, MS; Celorrio, M; Fernández-Suárez, D; Franco, R; González, H; Hillard, CJ; Oyarzabal, J; Pacheco, R; Riezu-Boj, JI; Ugarte, A, 2014) |
| "Treatment with probenecid prevented increased plasma creatinine and tubulointerstitial injuries, and reduced both the extent and the severity of ultrastructural lesions induced by aristolochic acid, such as the loss of brush border, mitochondrial edema, and the disappearance of mitochondrial crests." | 1.38 | Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy. ( Antoine, MH; Arlt, VM; Baudoux, TE; De Prez, EG; Goujon, JM; Nortier, JL; Pozdzik, AA; Quellard, N, 2012) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| "Probenecid treatment significantly reduced the neuronal loss and the number of neuronal intranuclear aggregates." | 1.35 | Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. ( Klivenyi, P; Vamos, E; Vecsei, L; Voros, K; Zadori, D, 2009) |
| " Although kynurenic acid does not cross the BBB, its precursor, kynurenine, if combined with probenecid, crosses it readily." | 1.34 | Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model. ( Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Mihály, A; Németh, H; Toldi, J; Vécsei, L, 2007) |
| " The present investigation tested the hypothesis of whether kynurenine in combination with systemically administered probenecid protects second-order trigeminal neurons against stimulation arriving via central processes of trigeminal ganglion cells." | 1.34 | Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid. ( Chadaide, Z; Fenyo, R; Knyihár-Csillik, E; Krisztin-Péva, B; Németh, H; Toldi, J; Vécsei, L, 2007) |
| "Wilson's disease is an inherited, autosomal recessive disorder of copper accumulation and toxicity." | 1.34 | Down-regulation of intestinal multidrug resistance-associated protein 2 in long-evans cinnamon rats. ( Chiba, M; Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M, 2007) |
| "These results support reactive gliosis as a means of striatal compensation for dopamine loss." | 1.32 | Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease. ( Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S, 2004) |
| "Acute renal failure was induced by occlusion of bilateral renal arteries for 60 min, and the motor activity and brain monoamine turnover were examined 48 h later." | 1.31 | Uraemia suppresses central dopaminergic metabolism and impairs motor activity in rats. ( Adachi, N; Arai, T; Deshpande, G; Lei, B; Nagaro, T; Seyfried, FJ; Shimizu, I, 2001) |
| " Controls over a 15-weeks period showed that this dosage did prevent the development of syphilitic orchitis and reactivity to the quantitative FTA-ABS-test." | 1.25 | [The effect of pivampicillin and probenecid on experimental syphilis in rabbits]. ( Petzoldt, D, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (13.04) | 18.7374 |
| 1990's | 3 (4.35) | 18.2507 |
| 2000's | 14 (20.29) | 29.6817 |
| 2010's | 34 (49.28) | 24.3611 |
| 2020's | 9 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Ohtsuki, S | 1 |
| Kikkawa, T | 1 |
| Mori, S | 1 |
| Hori, S | 1 |
| Takanaga, H | 1 |
| Otagiri, M | 1 |
| Terasaki, T | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Crocetti, L | 1 |
| Guerrini, G | 1 |
| Puglioli, S | 1 |
| Giovannoni, MP | 1 |
| Di Cesare Mannelli, L | 1 |
| Lucarini, E | 1 |
| Ghelardini, C | 1 |
| Wang, J | 2 |
| Dahl, G | 1 |
| Arkhipov, SN | 1 |
| Potter, DL | 1 |
| Sultanova, RF | 1 |
| Ilatovskaya, DV | 1 |
| Harris, PC | 1 |
| Pavlov, TS | 1 |
| Onusko, E | 1 |
| McDermott, MR | 1 |
| Robbins, N | 3 |
| Liu, G | 2 |
| Kranias, EG | 1 |
| Rubinstein, J | 3 |
| Koch, SE | 3 |
| Hong, F | 1 |
| Zheng, A | 1 |
| Xu, P | 1 |
| Xue, T | 1 |
| Dai, S | 1 |
| Pan, S | 1 |
| Guo, Y | 1 |
| Xie, X | 1 |
| Li, L | 1 |
| Qiao, X | 1 |
| Zhai, Y | 1 |
| Yang, W | 1 |
| Hao, W | 1 |
| Meng, Z | 1 |
| Ding, S | 1 |
| Li, X | 1 |
| Zhang, T | 1 |
| Huang, W | 1 |
| Xu, L | 1 |
| Zhang, Y | 1 |
| Yang, J | 1 |
| Gu, X | 1 |
| Wang, Q | 1 |
| Zhao, H | 1 |
| Gao, Y | 1 |
| Lu, J | 1 |
| Yu, W | 1 |
| He, F | 1 |
| Liu, W | 1 |
| Hisatome, I | 1 |
| Yamamoto, T | 1 |
| Wang, W | 1 |
| Cheng, J | 1 |
| Matsumoto, K | 1 |
| Suenaga, M | 1 |
| Mizutani, Y | 1 |
| Matsui, K | 1 |
| Yoshida, A | 1 |
| Nakamoto, T | 1 |
| Kato, S | 1 |
| Onódi, Z | 1 |
| Ruppert, M | 1 |
| Kucsera, D | 1 |
| Sayour, AA | 1 |
| Tóth, VE | 1 |
| Koncsos, G | 1 |
| Novák, J | 1 |
| Brenner, GB | 1 |
| Makkos, A | 1 |
| Baranyai, T | 1 |
| Giricz, Z | 1 |
| Görbe, A | 1 |
| Leszek, P | 1 |
| Gyöngyösi, M | 1 |
| Horváth, IG | 1 |
| Schulz, R | 1 |
| Merkely, B | 1 |
| Ferdinandy, P | 1 |
| Radovits, T | 1 |
| Varga, ZV | 1 |
| Freitas-Andrade, M | 1 |
| Bechberger, JF | 1 |
| MacVicar, BA | 1 |
| Viau, V | 1 |
| Naus, CC | 1 |
| Hainz, N | 3 |
| Becker, P | 1 |
| Rapp, D | 1 |
| Wagenpfeil, S | 2 |
| Wonnenberg, B | 2 |
| Beisswenger, C | 2 |
| Tschernig, T | 4 |
| Meier, C | 4 |
| Wolf, S | 2 |
| Beck, A | 1 |
| Dossi, E | 1 |
| Blauwblomme, T | 1 |
| Moulard, J | 1 |
| Chever, O | 1 |
| Vasile, F | 1 |
| Guinard, E | 1 |
| Le Bert, M | 1 |
| Couillin, I | 1 |
| Pallud, J | 1 |
| Capelle, L | 1 |
| Huberfeld, G | 1 |
| Rouach, N | 1 |
| Choi, JG | 2 |
| Huh, E | 1 |
| Ju, IG | 1 |
| Kim, N | 1 |
| Yun, J | 1 |
| Oh, MS | 2 |
| Spray, DC | 1 |
| Iglesias, R | 1 |
| Shraer, N | 1 |
| Suadicani, SO | 1 |
| Belzer, V | 1 |
| Hanstein, R | 1 |
| Hanani, M | 1 |
| Dosch, M | 1 |
| Zindel, J | 1 |
| Jebbawi, F | 1 |
| Melin, N | 1 |
| Sanchez-Taltavull, D | 1 |
| Stroka, D | 1 |
| Candinas, D | 1 |
| Beldi, G | 1 |
| de Marchi, FO | 1 |
| Cruz, FF | 1 |
| Menezes, FP | 1 |
| Kist, LW | 1 |
| Bogo, MR | 1 |
| Morrone, FB | 1 |
| Al-Jarrah, M | 2 |
| Obaidat, H | 1 |
| Bataineh, Z | 1 |
| Walton, L | 1 |
| Al-Khateeb, A | 1 |
| Alvarez-Fischer, D | 2 |
| Noelker, C | 1 |
| Grünewald, A | 1 |
| Vulinović, F | 1 |
| Guerreiro, S | 2 |
| Fuchs, J | 1 |
| Lu, L | 1 |
| Lombès, A | 1 |
| Hirsch, EC | 2 |
| Oertel, WH | 1 |
| Michel, PP | 2 |
| Hartmann, A | 2 |
| Penuela, S | 1 |
| Kelly, JJ | 1 |
| Churko, JM | 1 |
| Barr, KJ | 1 |
| Berger, AC | 1 |
| Laird, DW | 1 |
| Selvakumar, GP | 1 |
| Janakiraman, U | 2 |
| Essa, MM | 3 |
| Justin Thenmozhi, A | 2 |
| Manivasagam, T | 3 |
| Voss, M | 1 |
| Bischoff, M | 1 |
| Schirmer, SH | 1 |
| Langer, F | 1 |
| Bals, R | 1 |
| Fernández-Suárez, D | 1 |
| Celorrio, M | 1 |
| Riezu-Boj, JI | 1 |
| Ugarte, A | 1 |
| Pacheco, R | 1 |
| González, H | 1 |
| Oyarzabal, J | 1 |
| Hillard, CJ | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Fejes-Szabó, A | 1 |
| Bohár, Z | 1 |
| Nagy-Grócz, G | 1 |
| Vámos, E | 3 |
| Tar, L | 1 |
| Pődör, B | 1 |
| Tajti, J | 1 |
| Toldi, J | 4 |
| Vécsei, L | 6 |
| Párdutz, Á | 1 |
| Mori, Y | 1 |
| Tomonaga, D | 1 |
| Kalashnikova, A | 1 |
| Furuya, F | 1 |
| Akimoto, N | 1 |
| Ifuku, M | 1 |
| Okuno, Y | 1 |
| Beppu, K | 1 |
| Fujita, K | 1 |
| Katafuchi, T | 1 |
| Shimura, H | 1 |
| Churilov, LP | 1 |
| Noda, M | 1 |
| Bao, XQ | 1 |
| Wu, LY | 1 |
| Wang, XL | 1 |
| Sun, H | 1 |
| Zhang, D | 1 |
| Iracheta-Vellve, A | 1 |
| Petrasek, J | 1 |
| Satishchandran, A | 1 |
| Gyongyosi, B | 1 |
| Saha, B | 1 |
| Kodys, K | 1 |
| Fitzgerald, KA | 1 |
| Kurt-Jones, EA | 1 |
| Szabo, G | 1 |
| Ferguson, SA | 1 |
| Law, CD | 1 |
| Sarkar, S | 1 |
| Heng, Y | 1 |
| Zhang, QS | 1 |
| Mu, Z | 1 |
| Hu, JF | 1 |
| Yuan, YH | 1 |
| Chen, NH | 1 |
| Shi, X | 1 |
| Chen, YH | 1 |
| Liu, H | 1 |
| Qu, HD | 1 |
| Gu, PS | 1 |
| Moon, M | 1 |
| Dhanalakshmi, C | 1 |
| Song, BJ | 1 |
| Guillemin, GJ | 1 |
| Sas, K | 1 |
| Robotka, H | 1 |
| Rózsa, E | 1 |
| Agoston, M | 1 |
| Szénási, G | 1 |
| Gigler, G | 1 |
| Marosi, M | 1 |
| Kis, Z | 1 |
| Farkas, T | 1 |
| Hunot, S | 1 |
| Saurini, F | 1 |
| Marien, M | 1 |
| Sokoloff, P | 1 |
| Pothakos, K | 2 |
| Kurz, MJ | 2 |
| Lau, YS | 6 |
| Meredith, GE | 3 |
| Totterdell, S | 3 |
| Beales, M | 2 |
| Meshul, CK | 2 |
| Voros, K | 1 |
| Zadori, D | 1 |
| Klivenyi, P | 1 |
| Barber-Singh, J | 1 |
| Seo, BB | 1 |
| Nakamaru-Ogiso, E | 1 |
| Matsuno-Yagi, A | 1 |
| Yagi, T | 1 |
| Xu, G | 1 |
| Xiong, Z | 1 |
| Yong, Y | 1 |
| Wang, Z | 1 |
| Ke, Z | 1 |
| Xia, Z | 1 |
| Hu, Y | 1 |
| Yang, Z | 1 |
| Xiaohua, W | 1 |
| Lei, J | 1 |
| Ruoyun, T | 1 |
| Mingxia, X | 1 |
| Weichun, H | 1 |
| Li, F | 1 |
| Ping, W | 1 |
| Junwei, Y | 1 |
| Patki, G | 2 |
| Das-Panja, K | 1 |
| Le, WD | 1 |
| Ahmad, SO | 1 |
| Anandhan, A | 1 |
| Baudoux, TE | 1 |
| Pozdzik, AA | 1 |
| Arlt, VM | 1 |
| De Prez, EG | 1 |
| Antoine, MH | 1 |
| Quellard, N | 1 |
| Goujon, JM | 1 |
| Nortier, JL | 1 |
| Tranter, M | 1 |
| Luther, K | 1 |
| Singh, U | 1 |
| Jiang, M | 1 |
| Ren, X | 1 |
| Tee, T | 1 |
| Smith, L | 1 |
| Varma, P | 1 |
| Jones, WK | 1 |
| Carta, AR | 1 |
| Carboni, E | 1 |
| Spiga, S | 1 |
| Dervan, AG | 1 |
| McBean, GJ | 1 |
| Moore, C | 1 |
| Snyder, AK | 1 |
| Knyihár-Csillik, E | 2 |
| Mihály, A | 1 |
| Krisztin-Péva, B | 2 |
| Chadaide, Z | 2 |
| Németh, H | 2 |
| Fenyo, R | 2 |
| Novikova, L | 1 |
| Smirnova, IV | 1 |
| Stehno-Bittel, L | 1 |
| Chiba, M | 1 |
| Itagaki, S | 1 |
| Kobayashi, M | 1 |
| Hirano, T | 1 |
| Iseki, K | 1 |
| Bachmann, C | 1 |
| Colombo, JP | 1 |
| Bhattacharya, SK | 1 |
| Beal, MF | 2 |
| Petroske, E | 1 |
| Callen, S | 1 |
| Adachi, N | 1 |
| Lei, B | 1 |
| Deshpande, G | 1 |
| Seyfried, FJ | 1 |
| Shimizu, I | 1 |
| Nagaro, T | 1 |
| Arai, T | 1 |
| Musil, J | 1 |
| Sande, MA | 1 |
| Sherertz, RJ | 1 |
| Zak, O | 1 |
| Dacey, RG | 1 |
| Bodine, JA | 1 |
| Strausbaugh, LJ | 1 |
| Mendels, J | 1 |
| Frazer, A | 1 |
| Petzoldt, D | 1 |
| Nozaki, K | 1 |
| Riegels-Nielsen, P | 1 |
| Frimodt-Møller, N | 1 |
| Sørensen, M | 1 |
| Jensen, JS | 1 |
| Moroni, F | 1 |
| Lombardi, G | 1 |
| Carlà, V | 1 |
| Pellegrini, D | 1 |
| Carassale, GL | 1 |
| Cortesini, C | 1 |
| Morrison, RE | 1 |
| Harrison, SM | 1 |
| Tramont, EC | 1 |
| Ahtee, L | 1 |
| Eriksson, K | 1 |
1 review available for probenecid and Disease Models, Animal
| Article | Year |
|---|---|
Targeting TRPV1 and TRPV2 for potential therapeutic interventions in cardiovascular disease.
Topics: Animals; Capsaicin; Cardiotonic Agents; Cardiovascular Diseases; Disease Models, Animal; Humans; Mic | 2013 |
68 other studies available for probenecid and Disease Models, Animal
| Article | Year |
|---|---|
Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier.
Topics: Animals; Biological Transport; Blood-Brain Barrier; Capillaries; Disease Models, Animal; Estrone; Ma | 2004 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Design and synthesis of the first indole-based blockers of Panx-1 channel.
Topics: Animals; Binding Sites; Connexins; Disease Models, Animal; Drug Design; Humans; Indoles; Male; Membr | 2021 |
Probenecid slows disease progression in a murine model of autosomal dominant polycystic kidney disease.
Topics: Adenosine Triphosphate; Animals; Cysts; Disease Models, Animal; Disease Progression; Female; Humans; | 2023 |
Probenecid treatment improves outcomes in a novel mouse model of peripartum cardiomyopathy.
Topics: Animals; Apoptosis; Calcium Channels; Cardiomyopathies; Disease Models, Animal; Echocardiography; Fe | 2020 |
High-Protein Diet Induces Hyperuricemia in a New Animal Model for Studying Human Gout.
Topics: Allopurinol; Animal Structures; Animals; Chickens; Crystallization; Diet, High-Protein; Disease Mode | 2020 |
Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Gen | 2021 |
Uric acid inhibits HMGB1-TLR4-NF-κB signaling to alleviate oxygen-glucose deprivation/reoxygenation injury of microglia.
Topics: Animals; Cell Hypoxia; Cell Line; Cell Survival; Disease Models, Animal; Glucose; HMGB1 Protein; Inf | 2021 |
Role of transient receptor potential vanilloid subtype 2 in lower oesophageal sphincter in rat acid reflux oesophagitis.
Topics: Animals; Disease Models, Animal; Esophageal Sphincter, Lower; Gastroesophageal Reflux; Gene Expressi | 2021 |
AIM2-driven inflammasome activation in heart failure.
Topics: Adolescent; Adult; Aged; Animals; Calcium-Binding Proteins; CARD Signaling Adaptor Proteins; Case-Co | 2021 |
Pannexin1 knockout and blockade reduces ischemic stroke injury in female, but not in male mice.
Topics: Adjuvants, Pharmaceutic; Animals; Connexins; Disease Models, Animal; Female; Humans; Infarction, Mid | 2017 |
Probenecid-treatment reduces demyelination induced by cuprizone feeding.
Topics: Animals; Cuprizone; Demyelinating Diseases; Diet; Disease Models, Animal; Leukocytes; Lymphocytes; M | 2017 |
Probenecid arrests the progression of pronounced clinical symptoms in a mouse model of multiple sclerosis.
Topics: Animals; Cell Count; Disease Models, Animal; Disease Progression; Mice; Mice, Inbred C57BL; Multiple | 2017 |
Pannexin-1 channels contribute to seizure generation in human epileptic brain tissue and in a mouse model of epilepsy.
Topics: Adenosine Triphosphate; Animals; Brain; Cerebral Cortex; Connexins; Disease Models, Animal; Epilepsy | 2018 |
1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Choline O-Acetyltransferase; Disease Models, | 2018 |
Gap junction mediated signaling between satellite glia and neurons in trigeminal ganglia.
Topics: Animals; Boron Compounds; Carbenoxolone; Cells, Cultured; Disease Models, Animal; Female; Flufenamic | 2019 |
Connexin-43-dependent ATP release mediates macrophage activation during sepsis.
Topics: Adenosine Triphosphate; Animals; Autocrine Communication; Connexin 43; Disease Models, Animal; Gene | 2019 |
P2X7R and PANX-1 channel relevance in a zebrafish larvae copper-induced inflammation model.
Topics: Acetamides; Animals; Connexins; Copper; Disease Models, Animal; Female; Gene Expression Regulation; | 2019 |
Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Models, Animal; Male | 2013 |
Probenecid potentiates MPTP/MPP+ toxicity by interference with cellular energy metabolism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 2013 |
Panx1 regulates cellular properties of keratinocytes and dermal fibroblasts in skin development and wound healing.
Topics: Actins; Adjuvants, Pharmaceutic; Animals; Cell Differentiation; Connexins; Dermis; Disease Models, A | 2014 |
Escin attenuates behavioral impairments, oxidative stress and inflammation in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport | 2014 |
Probenecid reduces infection and inflammation in acute Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cytokines; Disease Models, Animal; Humans; Inflammatio | 2014 |
Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acids; Benzodioxoles; Corpus Striatum; Disease Models | 2014 |
Effect of probenecid on the pain-related behaviour and morphological markers in orofacial formalin test of the rat.
Topics: Analgesics; Animals; Disease Models, Animal; Facial Pain; Formaldehyde; Injections, Intraperitoneal; | 2015 |
Effects of 3,3',5-triiodothyronine on microglial functions.
Topics: Adenosine Triphosphate; Adjuvants, Pharmaceutic; Animals; Brain Injuries; Cell Movement; Cells, Cult | 2015 |
Squamosamide derivative FLZ protected tyrosine hydroxylase function in a chronic MPTP/probenecid mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Benzeneacetamides; Disease | 2015 |
Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice.
Topics: Adenosine Triphosphate; Adjuvants, Pharmaceutic; Allopurinol; Animals; Antimetabolites; Cells, Cultu | 2015 |
Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Disease Models, Animal; Hyp | 2015 |
Probenecid Application Prevents Clinical Symptoms and Inflammation in Experimental Autoimmune Encephalomyelitis.
Topics: Adjuvants, Pharmaceutic; Animals; Central Nervous System; Connexins; Disease Models, Animal; Encepha | 2016 |
Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Anti-Inflammatory Agents; Di | 2016 |
Therapeutic effects of paeonol on methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid-induced Parkinson's disease in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acetophenones; Animals; Behavior, Animal; Brain-Derive | 2016 |
Mulberry fruit ameliorates Parkinson's-disease-related pathology by reducing α-synuclein and ubiquitin levels in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Antioxidants; Corpus Striatu | 2017 |
Chronic mild stress augments MPTP induced neurotoxicity in a murine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Body Weight; Brain-D | 2017 |
Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus.
Topics: Adjuvants, Pharmaceutic; Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Elec | 2008 |
Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adjuvants, Pharmaceutic; Animals; Brain; Chromatograph | 2008 |
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Animals; Apoptosis; Autophagy; Biological Transport, Active; Disease Models | 2009 |
Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease.
Topics: Age Factors; Animals; Cell Count; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose | 2009 |
Neuroprotective effect of long-term NDI1 gene expression in a chronic mouse model of Parkinson disorder.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chronic Disease; Disease Mo | 2009 |
Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Cells, Cultured; Chronic Disease; Corp | 2010 |
Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells.
Topics: Animals; Blotting, Western; Cell Line; Disease Models, Animal; Epithelial Cells; Extracellular Matri | 2010 |
Neuroprotective effects and mechanisms of exercise in a chronic mouse model of Parkinson's disease with moderate neurodegeneration.
Topics: Adjuvants, Pharmaceutic; Animals; Biomarkers; Brain-Derived Neurotrophic Factor; Corpus Striatum; Di | 2011 |
Impact of exercise on mitochondrial transcription factor expression and damage in the striatum of a chronic mouse model of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Analysis of Variance; Animals; Chronic Disease; Corpus Striatum; Cytochrome | 2011 |
Protective compounds in animal models of trigeminal activation and neurodegeneration.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combi | 2012 |
Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apoptosis; bcl-2-Associated X P | 2013 |
Probenecid prevents acute tubular necrosis in a mouse model of aristolochic acid nephropathy.
Topics: Animals; Aristolochic Acids; Atrophy; Biomarkers; Cell Proliferation; Cell Survival; Creatinine; Cyt | 2012 |
Probenecid as a noninjurious positive inotrope in an ischemic heart disease murine model.
Topics: Administration, Oral; Animals; Calcium Signaling; Cardiotonic Agents; Cell Line; Cell Survival; Dise | 2013 |
The MPTP/probenecid model of progressive Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Chromatography, High Pressu | 2013 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; | 2004 |
Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Genes, fos; Immunohistochemistry; Kynure | 2007 |
Prevention of electrical stimulation-induced increase of c-fos immunoreaction in the caudal trigeminal nucleus by kynurenine combined with probenecid.
Topics: Adjuvants, Pharmaceutic; Afferent Pathways; Analgesics; Animals; Blood-Brain Barrier; Disease Models | 2007 |
Endurance exercise promotes cardiorespiratory rehabilitation without neurorestoration in the chronic mouse model of parkinsonism with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Calorimetry, Indirect; Citr | 2007 |
Down-regulation of intestinal multidrug resistance-associated protein 2 in long-evans cinnamon rats.
Topics: Animals; ATP-Binding Cassette Transporters; Disease Models, Animal; Down-Regulation; Hepatolenticula | 2007 |
Increased tryptophan uptake into the brain in hyperammonemia.
Topics: Amino Acids; Ammonia; Animals; Brain; Brain Stem; Disease Models, Animal; Indoles; Male; Probenecid; | 1983 |
Stress by restraining elevates brain prostaglandins in the rat.
Topics: Adrenalectomy; Animals; Brain Chemistry; Dinoprost; Dinoprostone; Disease Models, Animal; Male; Prob | 1982 |
Huntington's disease, behavioral disturbances, and kynurenines: preclinical findings and therapeutic perspectives.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Kynurenine; Papio; Probenecid; Rats; Re | 1996 |
Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Acute Disease; Animals; Axons; Brain; Cell Death; Chro | 2001 |
Uraemia suppresses central dopaminergic metabolism and impairs motor activity in rats.
Topics: Acute Kidney Injury; alpha-Methyltyrosine; Animals; Brain Chemistry; Coma; Confusion; Corpus Striatu | 2001 |
Physiological characteristics of various experimental models for the study of disorders in purine metabolism.
Topics: Acidosis; Alkalosis; Allopurinol; Animals; Cholesterol; Disease Models, Animal; Diuresis; Fructose; | 1977 |
Factors influencing the penetration of antimicrobial agents into the cerebrospinal fluid of experimental animals.
Topics: Animals; Cephalosporins; Disease Models, Animal; Meningitis; Penicillins; Probenecid; Protein Bindin | 1978 |
Reduced central serotonergic activity in mania: implications for the relationship between depression and mania.
Topics: Bipolar Disorder; Brain; Depression; Disease Models, Animal; Humans; Hydroxyindoleacetic Acid; Hypno | 1975 |
[The effect of pivampicillin and probenecid on experimental syphilis in rabbits].
Topics: Administration, Oral; Ampicillin; Animals; Disease Models, Animal; Drug Therapy, Combination; Humans | 1975 |
Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats.
Topics: Animals; Animals, Newborn; Brain Ischemia; Cerebral Cortex; Disease Models, Animal; Dose-Response Re | 1992 |
Synovectomy for septic arthritis. Early versus late synovectomy studied in the rabbit knee.
Topics: Administration, Oral; Animals; Arthritis, Infectious; Cloxacillin; Combined Modality Therapy; Diseas | 1991 |
Content of quinolinic acid and of other tryptophan metabolites increases in brain regions of rats used as experimental models of hepatic encephalopathy.
Topics: Acetates; Animals; Brain; Brain Stem; Cerebellum; Cerebral Cortex; Disease Models, Animal; Hepatic E | 1986 |
Oral amoxycillin, an alternative treatment for neurosyphilis.
Topics: Administration, Oral; Amoxicillin; Animals; Disease Models, Animal; Female; Humans; Male; Neurosyphi | 1985 |
5-Hydroxytryptamine and 5-hydroxyindolylacetic acid content in brain of rat strains selected for their alcohol intake.
Topics: Alcohol Drinking; Alcoholism; Animals; Body Temperature; Brain; Brain Chemistry; Disease Models, Ani | 1972 |